PROC vs. AQST, URGN, NBTX, EPIX, FBLG, VNDA, NLTX, CRMD, ORGO, and KMDA
Should you be buying Procaps Group stock or one of its competitors? The main competitors of Procaps Group include Aquestive Therapeutics (AQST), UroGen Pharma (URGN), Nanobiotix (NBTX), ESSA Pharma (EPIX), FibroBiologics (FBLG), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), CorMedix (CRMD), Organogenesis (ORGO), and Kamada (KMDA). These companies are all part of the "pharmaceutical preparations" industry.
Aquestive Therapeutics (NASDAQ:AQST) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Procaps Group has a net margin of 12.61% compared to Procaps Group's net margin of -55.85%. Aquestive Therapeutics' return on equity of 283.06% beat Procaps Group's return on equity.
In the previous week, Aquestive Therapeutics had 23 more articles in the media than Procaps Group. MarketBeat recorded 26 mentions for Aquestive Therapeutics and 3 mentions for Procaps Group. Aquestive Therapeutics' average media sentiment score of 0.30 beat Procaps Group's score of 0.29 indicating that Procaps Group is being referred to more favorably in the news media.
Aquestive Therapeutics has a beta of 2.95, meaning that its share price is 195% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Aquestive Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 146.91%. Procaps Group has a consensus price target of $4.50, indicating a potential upside of 63.64%. Given Procaps Group's stronger consensus rating and higher probable upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Procaps Group.
Procaps Group has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks.
32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.4% of Aquestive Therapeutics shares are held by insiders. Comparatively, 19.9% of Procaps Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aquestive Therapeutics received 195 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 66.67% of users gave Aquestive Therapeutics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.
Summary
Aquestive Therapeutics and Procaps Group tied by winning 9 of the 18 factors compared between the two stocks.
Get Procaps Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Procaps Group Competitors List
Related Companies and Tools
